Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:ageRange |
18 years and older
|
| gptkbp:allocates |
Randomized
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:clinicalTrialsGovURL |
https://clinicaltrials.gov/ct2/show/NCT03581786
|
| gptkbp:completedIn |
2022-12-31
|
| gptkbp:condition |
Esophageal Carcinoma
|
| gptkbp:enrollment |
749
|
| gptkbp:gender |
All
|
| https://www.w3.org/2000/01/rdf-schema#label |
NCT03581786
|
| gptkbp:intervention |
gptkb:Placebo
gptkb:Cisplatin gptkb:Pembrolizumab 5-Fluorouracil |
| gptkbp:location |
International (multiple countries)
|
| gptkbp:mask |
Double
|
| gptkbp:officialName |
A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy Versus Chemotherapy Alone as First-Line Therapy in Participants With Advanced Esophageal Carcinoma (KEYNOTE-590)
|
| gptkbp:primaryCompletionDate |
2020-01-31
|
| gptkbp:recognizedBy |
KEYNOTE-590
|
| gptkbp:result |
Overall Survival (OS)
Progression-Free Survival (PFS) |
| gptkbp:sponsor |
gptkb:Merck_Sharp_&_Dohme_LLC
|
| gptkbp:startDate |
2018-07-09
|
| gptkbp:studyType |
Interventional
|
| gptkbp:bfsParent |
gptkb:Toripalimab
|
| gptkbp:bfsLayer |
7
|